Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 264

1.

Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia.

Kane JM, Khanna S, Rajadhyaksha S, Giller E.

Int Clin Psychopharmacol. 2006 Jan;21(1):21-8.

PMID:
16317313
2.
3.

Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.

Olié JP, Spina E, Murray S, Yang R.

Int Clin Psychopharmacol. 2006 May;21(3):143-51.

PMID:
16528136
4.

Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies.

Lawson WB, Herman BK, Loebel A, Lazariciu I, Malik M.

CNS Spectr. 2009 Sep;14(9):478-86.

PMID:
19890230
5.

A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia.

Hirsch SR, Kissling W, Bäuml J, Power A, O'Connor R.

J Clin Psychiatry. 2002 Jun;63(6):516-23.

PMID:
12088164
6.

Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.

Citrome L, Meng X, Hochfeld M, Stahl SM.

Hum Psychopharmacol. 2012 Jan;27(1):24-32. doi: 10.1002/hup.1254. Epub 2011 Dec 7.

PMID:
22161738
7.

Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial.

Potkin SG, Keck PE Jr, Segal S, Ice K, English P.

J Clin Psychopharmacol. 2005 Aug;25(4):301-10.

PMID:
16012271
8.

Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation study.

Loebel AD, Khanna S, Rajadhyaksha S, Siu CO, Giller E, Potkin SG.

J Clin Psychiatry. 2007 Sep;68(9):1333-8.

PMID:
17915970
9.

An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.

Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner KD, Law CG, Ko GN.

J Clin Psychopharmacol. 1998 Aug;18(4):296-304.

PMID:
9690695
10.

Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.

Potkin SG, Weiden PJ, Loebel AD, Warrington LE, Watsky EJ, Siu CO.

Int J Neuropsychopharmacol. 2009 Oct;12(9):1233-48. doi: 10.1017/S1461145709000352. Epub 2009 May 7.

PMID:
19419595
11.
12.

The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.

Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y.

CNS Drugs. 2009;23(7):615-25. doi: 10.2165/00023210-200923070-00006.

PMID:
19552488
13.

A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms.

Kinon BJ, Lipkovich I, Edwards SB, Adams DH, Ascher-Svanum H, Siris SG.

J Clin Psychopharmacol. 2006 Apr;26(2):157-62.

PMID:
16633144
14.

Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.

Alptekin K, Hafez J, Brook S, Akkaya C, Tzebelikos E, Ucok A, El Tallawy H, Danaci AE, Lowe W, Karayal ON.

Int Clin Psychopharmacol. 2009 Sep;24(5):229-38. doi: 10.1097/YIC.0b013e32832c2624.

PMID:
19531959
15.

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW.

J Clin Psychiatry. 2002 Sep;63(9):763-71.

PMID:
12363115
16.

Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies.

Keck PE Jr, Reeves KR, Harrigan EP; Ziprasidone Study Group.

J Clin Psychopharmacol. 2001 Feb;21(1):27-35.

PMID:
11199944
17.

Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.

Zhao T, Park TW, Yang JC, Huang GB, Kim MG, Lee KH, Chung YC.

Int Clin Psychopharmacol. 2012 Jul;27(4):184-90. doi: 10.1097/YIC.0b013e3283528d22.

PMID:
22426471
18.

Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.

Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL.

J Clin Psychiatry. 2003 May;64(5):580-8.

PMID:
12755663
19.
20.

Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.

Ratner Y, Gibel A, Yorkov V, Ritsner MS.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Oct 1;31(7):1401-9. Epub 2007 Jun 21.

PMID:
17669574
Items per page

Supplemental Content

Write to the Help Desk